THERMO FISHER MICROBIOLOGY acquired by ASTORG
Context
Astorg has signed a definitive agreement to acquire Thermo Fisher Scientific's microbiology business, which will become an independent, privately owned platform, backed by Astorg. The transaction consists of a complete corporate carve-out, executed via the Astorg VIII fund, representing the vehicle's tenth investment to date and further concentrating its portfolio exposure within the life sciences sector. The ownership transition is driven by the seller’s strategic decision to divest non-core clinical assets, allowing the parent company to reallocate its corporate capital toward higher-growth molecular diagnostics. For the target company, the separation from a large corporate matrix removes internal budget competition and enables dedicated reinvestment into product innovation. The ownership transition establishes a clear operational mandate focused on scaling global market share, expanding the current commercial infrastructure, and pursuing consolidation via strategic mergers and acquisitions. The post-closing roadmap requires the execution of complex transitional service agreements to ensure continuity across thirteen global manufacturing and research facilities without disrupting ongoing supply contracts. The definitive agreement is subject to customary anti-trust clearances and regulatory approvals, with final closing projected during the second half of 2026.
THERMO FISHER MICROBIOLOGY, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
The microbiology division of Thermo Fisher Scientific, commercialized globally under the legacy Remel and Oxoid brands, operates as a developer and manufacturer of diagnostic consumables and equipment utilized in clinical, pharmaceutical, and food safety testing laboratories. The entity focuses on specialized culture media solutions and automated antimicrobial susceptibility testing systems designed for pathogen identification. These physical products represent critical operational components within specialized testing workflows where chemical exactness determines clinical outcomes. Revenue generation is driven by the regular replenishment of single-use testing consumables, which accounts for over 95% of total turnover across thirty-eight thousand active laboratories. This transacting mechanism benefits from deep institutional inertia as laboratories anchor their standardized daily testing protocols to the specific chemical profiles of these brands. Switching to alternative vendors requires extensive internal validation protocols and regulatory re-certification of testing lines, creating high friction and substantial financial switching barriers. Furthermore, the operational landscape is governed by increasingly rigid international public health mandates and pharmaceutical quality control laws. These strict baseline requirements compel testing facilities to rely exclusively on audited, established market suppliers, neutralizing commodity-grade competition.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (USD)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Life Sciences | Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Life Sciences | Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | Life Sciences | UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure |
| 04/2026 | DEVYSER DIAGNOSTICS | CYBERGENE | SWEDEN | Life Sciences | Devyser Diagnostics AB has finalized the acquisition of CyberGene AB from Level Bio AB. The strategic rationale for this transaction centers on a "portfolio-optimization" play, merging the target's established diagnostic kits in aneuploidy and infertility with the group's global commercial infrastructure and direct sales force |
| 04/2026 | VITREX MEDICAL GROUP | HERNIAMESH | ITALY | Life Sciences | Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Life Sciences | The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors |
| 04/2026 | RANTUM CAPITAL | TONTARRA MEDIZINTECHNIK | GERMANY | Life Sciences | Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Life Sciences | The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Life Sciences | American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena |
| 04/2026 | FOR TALENTS / UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Life Sciences | In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period |
REFERENCES
Valuation range: EV 1b - 4b USD
Revenue range: 450M - 900M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of THERMO FISHER MICROBIOLOGY by ASTORG are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Press release: view release
Acquirer: astorg